

# Noninvasive Cancer Diagnostics: Technologies and Global Markets

<https://marketpublishers.com/r/NF3608E0B9AEN.html>

Date: August 2017

Pages: 335

Price: US\$ 1,250.00 (Single User License)

ID: NF3608E0B9AEN

## Abstracts

The global market for noninvasive cancer diagnostics was valued at \$107.4 billion in 2016. This market is estimated to grow from nearly \$114.6 billion in 2017 to \$159.8 billion by 2022 with a compound annual growth rate (CAGR) of 6.9% for the period of 2017-2022.

Diagnostic imaging technologies, the leading segment of this market, will grow from \$43.6 billion in 2017 to \$58.5 billion by 2022 with a CAGR of 6.1%.

The market for advanced noninvasive approaches will grow from \$40.5 billion in 2017 to \$57.9 billion by 2022 with a CAGR of 7.4%.

## Contents

### **CHAPTER 1: INTRODUCTION**

Study Goals and Objectives  
Scope of Report  
Methodology and Information Sources  
Primary Data and Information Gathering  
Secondary Data and Information Gathering  
Market Share Analysis and Market Forecast Prediction  
Geographic Breakdown  
Analyst's Credentials  
Related BCC Research Reports

### **CHAPTER 2: SUMMARY AND HIGHLIGHTS**

Summary of Key Findings  
Diagnostic Imaging Segment  
Advanced Diagnostics Segment  
Conventional Segment

### **CHAPTER 3: MARKET AND TECHNOLOGY REVIEW: DIAGNOSTIC IMAGING**

Realtime In Vivo Cancer Diagnosis using Raman Spectroscopy  
InVivo Fluorescence Imaging in Personalized Cancer Diagnostics  
Direct Imaging  
Indirect Fluorescence Imaging  
Magnetic Resonance Imaging (MRI) Scans  
Development to the RF Subsystem  
Positron Emission Tomography (PET) Scan  
Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)  
Mammography  
Digital Mammography Systems  
Breast Tomosynthesis Systems  
Ultrasound  
Barium Swallow or Enema  
Bone Scans (MRI, CT and PET)  
Market Estimate

## **CHAPTER 4: MARKET AND TECHNOLOGY REVIEW: ADVANCED NONINVASIVE CANCER**

Diagnostic Assays and Technologies

Introduction to Circulating Nucleic Acids (CNAs)

Circulating Nucleic Acids as a Diagnostic Tool

Circulating DNA as a Biomarker of Cancer

Use of Circulating DNA for Prenatal Diagnosis (Conventional)

Use of Circulating DNA for Prenatal Diagnosis (Noninvasive)

Circulating RNA as a Biomarker of Cancer

Methods Used for the Detection of Circulating Nucleic Acids

Liquid Biopsy

Janssen Diagnostics

Roche Molecular Systems Inc.

Genomic Health

Foundation Medicine

Veracyte 60Trovagene Inc.

Myriad Genetics

OncoCyte Corp.

Illumina

NeoGenomics Laboratories

Biocept Inc.

Vermillion Inc.

Sysmex Inostics, a subsidiary of Sysmex Corp.

Guardant Health

Product Development and New Initiatives in Liquid Biopsy

Molecular Cytogenetic/Gene Expression Studies

Amplify and Detect Diminished Amounts of RNA Consistently

Analyze Hundreds of Genes

Proteomics and New Protein Markers

Inside the ProteinChip System

Proteome Pattern Recognition

NextGeneration Sequencing (NGS) Studies

Illumina Solexa System

Roche 454 Sequencing

Thermo Fisher Scientific Ion Personal Genome Machine (PGM)

Thermo Fisher Scientific SOLiD (Sequencing by Oligonucleotide Ligation and Detection)

Oxford Nanopore Technologies

The ThirdGeneration Sequencer

Clinical Acceptance of a New Diagnostic Assay

SalivaBased Oral Cancer Diagnostics

Advanced Tissue Staining (Immunohistochemistry (IHC) and in situ Hybridization (ISH))

Optical Biopsy

Market Estimate

## **CHAPTER 5: MARKET AND TECHNOLOGY REVIEW: CONVENTIONAL NONINVASIVE CANCER**

Diagnostic Assays and Tests

Pap Test and HPV Testing

Tumor Biomarker Testing

MammaPrint Specifications

Genomic Health's Oncotype DX Breast Cancer Test

The Prosigna Breast Cancer Prognostic Gene Signature Assay (formerly called the PAM50 test)

Sales and Marketing Strategies for Cancer Tests

Fecal Occult Blood Tests (FOBT)

Digital Rectal Exam (DRE)

Multigated Acquisition (MUGA) Scans

Market Estimate

## **CHAPTER 6: INCIDENCE, PREVALENCE AND MORTALITY STATISTICS FOR CANCER: A GLOBAL**

Summary

Cancer: The Disease

Cancer: A Statistical Analysis of the Disease Incidence and Prevalence

Incidence and Prevalence Rates for Major Cancer Types

Regional Patterns of Cancer

Europe

North America

AsiaPacific

Latin and Central America

Middle East/Africa

The Global Cancer Burden and Worldwide Cancer Risk Factors

Tobacco Use and Statistics

Alcohol Abuse and Cancer Statistics

Obesity and Cancer Statistics

Infectious Diseases and Cancer  
Inherited Genes/Diseases and Cancer  
Sun, U.V. and Cancer  
Hormones and Cancer

## **CHAPTER 7: NONINVASIVE CANCER DIAGNOSTICS MARKET BY CANCER TYPE**

Global Noninvasive Cancer Diagnostics Market, by Cancer Type  
Global Market Drivers  
Global Market Restraints  
Regional Noninvasive Cancer Diagnostics Market Assessment: North America  
Selected Market Drivers: North America  
Selected Market Restraints: North America  
Selected Country: Noninvasive Cancer Diagnostics Market, by Cancer Type  
Regional Noninvasive Cancer Diagnostics Market Assessment: Europe  
Selected Market Drivers: Europe  
Selected Market Restraint: Europe  
Selected Country: Noninvasive Cancer Diagnostics Market, by Cancer Type  
Regional Noninvasive Cancer Diagnostics Market Assessment: AsiaPacific  
Selected Market Drivers: AsiaPacific  
Selected Market Restraints: AsiaPacific  
Regional Noninvasive Cancer Diagnostics Market Assessment: Central and Latin America  
Selected Market Drivers: Central and Latin America  
Selected Market Restraints: Central and Latin America  
Regional Noninvasive Cancer Diagnostics Market Assessment: Middle East/Africa  
Selected Market Drivers: Middle East/Africa  
Selected Market Restraints: Middle East/Africa

## **CHAPTER 8: MARKET ANALYSIS BY TECHNOLOGY, END USER AND MARKET SHARE**

Global Noninvasive Cancer Diagnostics Market, by Technology  
Regional Noninvasive Cancer Diagnostics Market, by Technology: North America  
Regional Noninvasive Cancer Diagnostics Market, by Technology: Europe  
Regional Noninvasive Cancer Diagnostics Market, by Technology: AsiaPacific  
Regional Noninvasive Cancer Diagnostics Market, by Technology: Central and Latin America  
Regional Noninvasive Cancer Diagnostics Market, by Technology: Middle East/Africa

Global Noninvasive Cancer Diagnostics Market, by EndUser

General Clinical Reference Laboratories

Market Share Analysis by Technology: Noninvasive Cancer Diagnostics Market

## **CHAPTER 9: TECHNOLOGICAL ADVANCES, TRENDS AND OPPORTUNITIES**

Key Technological Developments and Advances, Market Trends and Opportunities

Developments and Advances, Trends and Opportunities in Diagnostic Imaging

Developments and Advances, Trends and Opportunities in Advanced Noninvasive Approaches

Developments and Advances, Trends and Opportunities in Screening Assays

Opportunities for IVDMA Companies

## **CHAPTER 10: REGULATORY AND LEGISLATIVE REQUIREMENTS**

United States

How are IVDs Classified?

FDA Regulations Relating to Companion Diagnostics

Laboratory Developed Tests (LDTs)

Centers for Medicare & Medicaid Services (CMS)

The 2010 Affordable Care Act

Private Insurance

Europe 231 (General) Medical Device Directive, MDD (93/42/EEC)

Active Implantable Medical Device Directive, AIMDD (90/383/EEC)

In Vitro Diagnostic Medical Device Directive, IVDMDD (98/79/EC)

Proposal for Changes to the Medical Device Directive, MDD (93/42/EEC)

Japan

Marketing Authorization System

China

Overview of the Healthcare System

Healthcare Reforms

Healthcare Institutions

India

Overview of the Healthcare System

Hospital Resources

Population Statistics

South Korea

Brazil

Background

Regulatory and Legislative Requirements  
Market Entry and Reimbursement of Medical Devices: Brazil  
Argentina  
Background  
Governmentfunded Public Health Sector  
Social Health Insurance Sector  
Private Sector  
Regulatory and Legislative Requirements  
Mexico  
Legislation and Regulations Governing Medical Devices in Mexico  
Health Insurance Structure in Mexico

## **CHAPTER 11: PATENT REVIEW OF KEY TECHNOLOGIES**

Microarray Patents  
LOAC Patents  
Clinical NextGeneration Sequencing (NGS) Patents  
Clinical NGS Patents Summary  
Clinical NGS Patents by Indication

## **CHAPTER 12: COMPANY PROFILES**

Appendix A: Company Addresses and Contact Details  
Appendix B: Government Regulatory Agencies and Professional Organizations  
Appendix C: Commonly Used Acronym Associated with Noninvasive Cancer  
Diagnostics  
About BCC Research  
About BCC Research  
BCC Membership  
BCC Custom Research

## List Of Tables

### LIST OF TABLES

Summary Table Global Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 (\$ Millions)

Table 1 Diagnostic Imaging Segment

Table 2 Advanced Segment

Table 3 Conventional Segment

Table 4 Noninvasive Cancer Diagnostics Market Segmentation

Table 5 Breast MRI Systems Currently Available

Table 6 Wide Bore MRI Systems Currently Available

Table 7 PET/CT Systems Currently Available

Table 8 PET/MR Systems Currently Available

Table 9 Key trends in (Digital Mammography Systems)

Table 10 Digital Mammography Systems Currently Available

Table 11 Breast Tomosynthesis Systems Currently Available

Table 12 Benefits of Medical Ultrasound Imaging

Table 13 Regulatory Approval for Highintensity Focused Ultrasound (HIFU) by Region

Table 14 Ultrasound Systems Currently Available

Table 15 Noninvasive Cancer Diagnostics Market Segmentation

Table 16 Major Developments in Understanding Nucleic Acids and their Cellular Roles

Table 17 Circulating Tumorassociated miRNAs as Potential Cancer Biomarkers

Table 18 Key Elements for Business Competition in Gene Expression Profiling for Cancer

Table 19 DNA Microarray Diagnostic Test Adoption Rate

Table 20 Characteristics of in situ Hybridization Methods

Table 21 Key Advantages of Optical Biopsy Systems

Table 22 Noninvasive Cancer Diagnostics Market Segmentation

Table 23 Key Drivers to Adoption of Biomarkers in Clinical Use

Table 24 Key Barriers to Adoption of Biomarkers in Clinical Use

Table 25 Tumor Biomarkers Currently in Common Clinical Use

Table 26 MammaPrint: Key Features

Table 27 Strategies for Marketing Cancer Diagnostic Products

Table 28 Advantages of Fecal Occult Blood Test (Guaiac FOBT or Fecal Immunochemical Test (FIT))

Table 29 Disadvantages of Fecal Occult Blood Test (Guaiac FOBT or Fecal Immunochemical Test (FIT))

Table 30 Summary Statistics (Global): Estimated Incidence, Mortality and FiveYear



Prevalence, 2012

Table 31 Summary Statistics (Global): Estimated Incidence, Mortality and FiveYear Prevalence (In Men and Women Combined) by Cancer Type, 2012

Table 32 Summary Statistics (Global): Estimated Incidence, Mortality and FiveYear Prevalence (Men) by Cancer Type, 2012

Table 33 Summary Statistics (Global): Estimated Incidence, Mortality and FiveYear Prevalence (Women) by Cancer Type, 2012

Table 34 Estimated Number of New Cancer Cases by Sex: United States, 2017 (%)

Table 35 Estimated Number of Deaths from Cancer by Sex: United States, 2017

Table 36 Global Noninvasive Cancer Diagnostics Market, Through 2022 (\$ Millions)

Table 37 Global Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)

Table 38 Global Noninvasive Cancer Diagnostics Market and Market Share, by Cancer Type, 2017 (%)

Table 39 Global Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)

Table 40 North American Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)

Table 41 Sample Listing of Payers that Published Positive Coverage Policies for KRAS Testing

Table 42 United States Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)

Table 43 Canada Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)

Table 44 European Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)

Table 45 Europe: Noninvasive Cancer Diagnostics Market, by Region, 2017 (%)

Table 46 France Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)

Table 47 Germany Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)

Table 48 Italy Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)

Table 49 Spain Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)

Table 50 U.K. Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)

Table 51 Benelux Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)

Table 52 Scandinavia Noninvasive Cancer Diagnostics Market, by Cancer Type,

Through 2022 (\$ Millions)

Table 53 Rest of Europe Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)

Table 54 AsiaPacific: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)

Table 55 AsiaPacific: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)

Table 56 China: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)

Table 57 India: Noninvasive Cancer Diagnostics Market, by Cancer Type, through 2022 (\$ Millions)

Table 58 Japan: Noninvasive Cancer Diagnostics Market, by Cancer Type, through 2022 (\$ Millions)

Table 59 South Korea: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)

Table 60 Rest of AsiaPacific: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)

Table 61 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)

Table 62 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Region, 2017 (%)

Table 63 Argentina: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)

Table 64 Brazil: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)

Table 65 Chile: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)

Table 66 Mexico: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)170

Table 67 Rest of Central and Latin America: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)

Table 68 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)

Table 69 Middle East/Africa: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)

Table 70 Middle East: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)

Table 71 Africa: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)

Table 72 Global Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 (\$ Millions)

Table 73 Global Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 (\$ Millions)

Table 74 Global Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 (\$ Millions)

Table 75 Global Noninvasive Cancer Diagnostics Market, by Conventional Noninvasive Cancer Screening and Diagnostic Assays and Tests Technology, Through 2022 (\$ Millions)

Table 76 North America: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 (\$ Millions)

Table 77 North American: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 (\$ Millions)

Table 78 North American: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 (\$ Millions)

Table 79 North American: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 (\$ Millions)

Table 80 Europe: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 (\$ Millions)

Table 81 Europe: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 (\$ Millions)

Table 82 Europe: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 (\$ Millions)

Table 83 Europe: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 (\$ Millions)

Table 84 AsiaPacific: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 (\$ Millions)

Table 85 AsiaPacific: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 (\$ Millions)

Table 86 AsiaPacific: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 (\$ Millions)

Table 87 AsiaPacific: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 (\$ Millions)

Table 88 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 (\$ Millions)

Table 89 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 (\$ Millions)

Table 90 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 (\$ Millions)

Table 91 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 (\$ Millions)

Table 92 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 (\$ Millions)

Table 93 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 (\$ Millions)

Table 94 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 (\$ Millions)

Table 95 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 (\$ Millions)

Table 96 Global Noninvasive Cancer Diagnostics Market, by EndUser, Through 2022 (\$ Millions)

Table 97 Global Market Share for Diagnostic Imaging, Noninvasive Cancer Diagnostics, by Company, 2017 (%)

Table 98 Global Market Share for Advanced Noninvasive Approaches, Noninvasive Cancer Diagnostics, by Company, 2017 (%)

Table 99 Global Market Share for Molecular SignatureBased Noninvasive Cancer Diagnostics, by Company, 2017 (%)

Table 100 Global Market Share for DNA MicroarrayBased Noninvasive Cancer Diagnostics, by Company, 2017 (%)

Table 101 Global Market Share for Cytogenetic/Gene ExpressionBased Noninvasive Cancer Diagnostics, by Company, 2017 (%)

Table 102 Global Market Share for Circulating Nucleic Acid (CNA)Based Noninvasive Cancer Diagnostics, by Company, 2017 (%)

Table 103 Global Market Share for Screening Assays, Noninvasive Cancer Diagnostics, by Company, 2017 (%)

Table 104 Global Market Share for Fecal Occult Blood Test (FOBT)Based Noninvasive Cancer Diagnostics, by Company, 2017 (%)

Table 105 Global Market Share for Tumor Biomarker TestBased Noninvasive Cancer Diagnostics, by Company, 2017 (%)

Table 106 Principal Factors Influencing the Growth and Development of Noninvasive Cancer Diagnostics, 2017

Table 107 Uses of Tumor Biomarkers in Drug Development

Table 108 Utility of Biomarkers as Companion Diagnostics to Drug Development

Table 109 Overview of Pharmaceutical Affair Law (PAL) and Japanese Medical Device Nomenclature (JMDN) Codes and Related Codes according to the EU MDD

Table 110 Number of Healthcare Institutions According to Ownership in China, 2010

Table 111 Total Number of Hospitals by Ranking in China, 2010

Table 112 Overview of Healthcare in India

Table 113 DNA Microarray Patents by Region, 2002-2012	
Table 114 Microarray-Related Proteomics Patents by Region, 2002 – 2012	
Table 115 Microarray-Related Patents by Application and Title, 2017	
Table 116 Patent Application and Title: Noninvasive Cancer Diagnostics, 2001 – Present	
Table 117 LOAC-Related Proteomics Patents by Region, 2002 – 2012	
Table 118 LOAC-Related Patents by Application and Title, 2013 – 2015	
Table 119 Clinical Next Generation Sequencing Patents, 2002–2012	
Table 120 Clinical NGS-Related Patents by Application and Title, 2013 – 2015	
Table 121 Clinical NGS Patents by Indication, 2002–2012	
Table 122 Abbott Laboratories: Company Financials, Through 2016 (\$ Millions)	
Table 123 Bayer AG: Company Financials, Through 2016 (\$ Millions)	
Table 124 bioMerieux S.A. Sales by Application, Through 2016 (\$ Millions)	
Table 125 Exact Sciences Corp.: Company Financials, Through 2016 (\$ Millions/%)	
Table 126 Hologic Inc.: Company Financials, 2015-2016 (\$ Millions)	
Table 127 Illumina, Inc: Company Financials, 2014-2016 (\$ Millions)	
Table 128 Myriad Genetics Inc. Financials, 2014-2016 (\$ Millions)	
Table 129 Philips Healthcare Financials, Through 2016 (\$ Millions)	
Table 130 Philips Group Financials by Segment, 2016 (\$ Millions)	
Table 131 Qiagen N.V. Financials, Through 2016 (\$ Millions)	
Table 132 Qiagen N.V. Financials by Region, Through 2016 (\$ Millions)	
Table 133 Quest Diagnostics Financials, Through 2016 (\$ Millions)	
Table 134 Roche Group Financials, Through 2016 (\$ Millions)	322
Table 135 Diagnostics Division Financials, 2015 and 2016 (\$ Millions)	
Table 136 Thermo Fisher Scientific Inc. Financials, Through 2016 (\$ Millions)	
Table 137 Company Addresses and Contact Details	
Table 138 Government Regulatory Agencies and Professional Organizations Associated with Noninvasive Cancer Diagnostics	
Table 139 Commonly Used Acronym Associated with Noninvasive Cancer Diagnostics	

## List Of Figures

### LIST OF FIGURES

Summary Figure Global Noninvasive Cancer Diagnostics Market, by Technology, 2016-2022 (\$ Millions)

Figure 1 Top Molecular CNA Characterization Techniques (%)

Figure 2 Market Growth and Evolution of MDx Cancer Biomarkers

Figure 3 Estimated Global Cancer Incidence Proportions by Major Sites, In Men and Women Combined, 2012 (%)

Figure 4 Estimated World Cancer Incidence Proportions by Major Sites, In Men, 2012 (%)

Figure 5 Estimated World Cancer Incidence Proportions by Major Sites, In Women, 2012 (%)

Figure 6 Global Market Share for Noninvasive Cancer Diagnostics, by Cancer Type, 2017 (%)

Figure 7 Global Noninvasive Cancer Diagnostics Market, by Region, 2017 (%)

Figure 8 Average Number of New Cases per Year and Age-Specific Incidence Rates for all Cancers in the U.K., 2012-2014

Figure 9 Europe: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)

Figure 10 Asia-Pacific: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)

Figure 11 Central and Latin America: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)

Figure 12 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Region, 2017 (%)

Figure 13 Global Noninvasive Cancer Diagnostics Market, by Technology Type, 2016-2022 (\$ Millions)

Figure 14 Global Noninvasive Cancer Diagnostics Market, by End-User, 2016-2022 (\$ Millions)

Figure 15 Tumor Biomarker Developments and Market Applications (%)

Figure 16 Private Health Insurance Coverage among Persons Under 65 in United States, 2007-2011 (Millions/Percent)

Figure 17 The Chinese Healthcare System



## I would like to order

Product name: Noninvasive Cancer Diagnostics: Technologies and Global Markets

Product link: <https://marketpublishers.com/r/NF3608E0B9AEN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NF3608E0B9AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970